BIIB vs NVAX · P/E 21, rev $9.89B vs P/E 2.5, rev $196.2M
Biogen Inc (BIIB) versus Novavax Inc (NVAX) — a side-by-side from cached financials, not a winner call.
Biogen Inc (BIIB) is a drug manufacturers - general company listed on NASDAQ. It is led by Christopher A. Viehbacher.
Novavax Inc (NVAX) is a biotechnology company listed on US.
Latest reported BIIB revenue for 2025-12-31 was $9.89B. Net income was $1.29B. Revenue was up 2.2% from 2024-12-31 to 2025-12-31. BIIB currently screens at market cap $29.33B and trailing P/E 21.4.
Latest reported NVAX revenue for 2026-06-30 was $196.2M. Net income was -$62.9M. Revenue was up 40.6% from 2026-03-31 to 2026-06-30. NVAX currently screens at market cap $1.09B and trailing P/E 2.5.
BIIB currently screens at market cap $29.33B and trailing P/E 21.4. NVAX currently screens at market cap $1.09B and trailing P/E 2.5.
Not investment advice. Open the BIIB and NVAX stock pages for the full models.
Not investment advice.